NORTHFIELD
LABORATORIES INC

1560 SHERMAN AVENUE
SUITE 1000
EVANSTON, IL 60201-4800
(847) 864-3500
FAX: (847) 864-0353
www.northfieldlabs.com
e-mail: nfld@northfieldlabs.com

6729 '04 MAR -5 .9:08

VIA FEDERAL EXPRESS

Docket Number 95S-0158 (BB IND # 10719)
Dockets Management Branch
Food and Drug Administration
Room 1061, Mail Stop HFA-305
5630 Fisher's Lane
Rockville, MD 20852

March 4, 2004

RE: BB IND 10719, POLY-SFH-P INJECTION [Polymerized Human Hemoglobin (Pyridoxylated), PolyHeme®]
Protocol RTBSE-11-(N): Publicly Disclosed Information

Dear Sir:

Reference is made to our Investigational New Drug Application (IND) for Poly-SFH-P Injection for acute trauma, BB IND # 10719, which was originally submitted to the Office of Blood Products on October 8, 2002 (Serial No. 000). Please also refer to Protocol RTBSE-R1-11-(N) entitled "A Phase III Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception from Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection [Polymerized Human Hemoglobin (Pyridoxylated), PolyHeme®] When Used to Treat Patients in Hemorrhagic Shock Following Traumatic Injuries".

In conformance with 21 CFR 312.54(a) and the Draft Guidance for Industry entitled *Exception from Informed Consent Requirements for Emergency Research* (March 30, 2000) which require that Institutional Review Board (IRB) information concerning public disclosure be submitted to this Docket for clinical investigations involving an exception from informed consent [21 CFR 50.24(a)(7)(iii)], we provide documentation for the following site:

95S-0158 RPT 17

Lehigh Valley Hospital
Cedar Crest & I-78
Allenton, PA 18103
IRB: Lehigh Valley Hospital IRB Health Studies Research

A copy of this submission is being submitted to BB IND #10719.

If you have any comments or questions, please contact the undersigned at 847-864-3500.

Sincerely,



Steven A. Gould, M.D.
Chairman and Chief Executive Officer